A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
This is an open label, multi-centre, Phase 1/2 dose escalation study of BBI608 administered
in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with
and without bevacizumab, or regorafenib, or irinotecan.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society